Overcoming platinum resistance in ovarian carcinoma

Expert Opinion on Investigational Drugs

Volumn 19, Issue 11, 2010, Pages 1339-1354

  Matsuo, Koji ^a   Lin, Yvonne G ^a,b   Roman, Lynda D ^a   Sood, Anil K ^c,d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

clinical trial; gemcitabine; ovarian cancer; platinum resistance; recurrence; review

Indexed keywords

ANTINEOPLASTIC AGENT; BELOTECAN; BEVACIZUMAB; CANFOSFAMIDE; CAPECITABINE; CARBOPLATIN; CISPLATIN; CRYPTOPHYCIN 52; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEFITINIB; GEMCITABINE; GOSERELIN; IFOSFAMIDE; IMATINIB; IRINOTECAN; IXABEPILONE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; TAMOXIFEN; TOPOTECAN; TRABECTEDIN; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; HUMAN; MEDLINE; MONOTHERAPY; OVARY CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS;

EID: 77958500057     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2010.515585     Document Type: Review

References (91)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010. [Epub ahead of print]
2. Omura G, Blessing JA, Ehrlich CE, et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer 1986;57:1725-30
3. Matsuo K, Bond VK, Eno ML, et al. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer. Int J Cancer 2009;125:2721-7
4. Matsuo K, Eno ML, Im DD, et al. Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma. Gynecol Oncol 2010;116:61-5
5. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991;9:389-93
6. Gore ME, Fryatt I, Wiltshaw E, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 1990;36:207-11
7. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16
8. Herzog TJ, Powell MA, Rader JS, et al. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer. Gynecol Oncol 2008;111:467-73
9. Peters GJ, Van Moorsel CJ, Lakerveld B, et al. Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or-resistant human ovarian cancer cell lines. Int J Oncol 2006;28:237-44
10. Wynne P, Newton C, Ledermann JA, et al. Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy. Br J Cancer 2007;97:927-33
11. Van Moorsel CJ, Pinedo HM, Veerman G, et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 1999;80:981-90
12. Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 2007;25:2811-18
13. Galligioni E, Arcuri C, Sorio R, Griso C. Gemcitabine and anthracyclines in platinum-resistant ovarian cancer. Ann Oncol 2006;17(Suppl 5):v195-8
14. Pectasides D, Xiros N, Papaxoinis G, et al. Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma. Gynecol Oncol 2008;108:47-52
15. Petru E, Angleitner-Boubenizek L, Reinthaller A, et al. Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and-resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study. Gynecol Oncol 2006;102:226-9
16. Skarlos DV, Kalofonos HP, Fountzilas G, et al. Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study. Anticancer Res 2005;25:3103-8
17. Ray-Coquard I, Weber B, Cretin J, et al. Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group. Br J Cancer 2009;100:601-7
18. Harnett P, Buck M, Beale P, et al. Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study. Int J Gynecol Cancer 2007;17:359-66
19. Bozas G, Bamias A, Koutsoukou V, et al. Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma. Gynecol Oncol 2007;104:580-5
20. Brewer CA, Blessing JA, Nagourney RA, et al. Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2006;103:446-50
21. GoffBA, Holmberg LA, Veljovich D, Kurland BF. Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium. Gynecol Oncol 2008;110:146-51
22. Greggi S, Salerno MG, D'Agostino G, et al. Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer. Oncology2001;60:19-23
23. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 1997;54(Suppl 4):15-21
24. Strauss HG, Hemsen A, Karbe I, et al. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer. Anticancer Drugs 2008;19:541-5
25. Chou HH, Wang KL, Chen CA, et al. Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up. Gynecol Oncol 2006;101:423-8
26. Verhaar-Langereis M, Karakus A, van Eijkeren M, et al. Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer. Int J Gynecol Cancer 2006;16:65-70
27. Rose PG, Smrekar M, Haba P, et al. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer. Am J Clin Oncol 2008;31:476-80
28. Sood AK, Lush R, Geisler JP, et al. Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial. Clin Cancer Res 2004;10:6080-5
29. Zwelling LA, Kohn KW. Mechanism of action of cis-dichlorodiammineplatinum (II). Cancer Treat Rep 1979;63:1439-44
30. Polyzos A, Kosmas C, Tsavaris N, et al. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel. Anticancer Res 2007;27:1645-51
31. Morgan RJ Jr, Synold TW, Gandara D, et al. Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: a California Cancer Consortium Trial. Int J Gynecol Cancer 2007;17:373-8
32. Sharma R, Graham J, Mitchell H, et al. Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer. Br J Cancer 2009;100:707-12
33. Cadron I, Leunen K, Amant F, et al. The 'Leuven' dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer. Gynecol Oncol 2007;106:354-61
34. Polyzos A, Gogas H, Markopoulos C, et al. Salvage chemotherapy with oxaliplatin and capecitabine for breast cancer patients pretreated with anthracyclines and taxanes. Anticancer Res 2009;29:2851-6
35. See HT, Freedman RS, Kudelka AP, et al. Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance. Int J Gynecol Cancer 2005;15:209-16
36. Polyzos A, Tsavaris N, Gogas H, et al. Cisplatin-Ifosfamide-gemcitabine as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and Paclitaxel. Anticancer Res 2009;29:2681-6
37. Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998;9:1053-71
38. Fu S, Kavanagh JJ, Hu W, Bast RC Jr. Clinical application of oxaliplatin in epithelial ovarian cancer. Int J Gynecol Cancer 2006;16:1717-32
39. Garmann D, Warnecke A, Kalayda GV, et al. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells. J Control Release 2008;131:100-6
40. Marques-Gallego P, den Dulk H, Brouwer J, et al. Cytotoxic activity and cellular processing in human ovarian carcinoma cell lines of a new platinum (II) compound containing a fluorescent substituted propylene diamine ligand. Biochem Pharmacol 2009;78:365-73
41. Markman M, Blessing J, Rubin SC, et al. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol 2006;101:436-40
42. Le T, Hopkins L, Baines KA, et al. Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer. Gynecol Oncol 2006;102:49-53
43. Hurt JD, Richardson DL, Seamon LG, et al. Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer. Gynecol Oncol 2009;115:396-400
44. Tinker AV, Gebski V, Fitzharris B, et al. Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel-ANZGOG 02-01. Gynecol Oncol 2007;104:647-53
45. Francis P, Schneider J, Hann L, et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 1994;12:2301-8
46. Katsumata N, Tsunematsu R, Tanaka K, et al. A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese cooperative study. Ann Oncol 2000;11:1531-6
47. Markman M, Zanotti K, Webster K, et al. Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum. Gynecol Oncol 2003;91:573-6
48. Berkenblit A, Seiden MV, Matulonis UA, et al. A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol Oncol 2004;95:624-31
49. Burger RA. Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 2007;25:2902-8
50. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:5180-6
51. Jurado JM, Sanchez A, Pajares B, et al. Combined oral cyclophosphamide and bevacizumab in heavily pretreated ovarian cancer. Clin Transl Oncol 2008;10:583-6
52. Wright JD, Hagemann A, Rader JS, et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer 2006;107:83-9
53. De Geest K, Blessing JA, Morris RT, et al. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum-and taxane-resistant ovarian or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2010;28:149-53
54. Miller DS, Blessing JA, Waggoner S, et al. Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2005;96:67-71
55. Miller DS, Blessing JA, Krasner CN, et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol 2009;27:2686-91
56. Vergote I, Calvert H, Kania M, et al. A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. Eur J Cancer 2009;45:1415-23
57. DAgostino G, del Campo J, Mellado B, et al. A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer. Int J Gynecol Cancer 2006;16:71-6
58. Lee HP, Seo SS, Ryu SY, et al. Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or-resistant ovarian cancer. Gynecol Oncol 2008;109:359-63
59. Hasan J, Ton N, Mullamitha S, et al. Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer. Br J Cancer 2005;93:647-51
60. Wagner U, du Bois A, Pfisterer J, et al. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy-a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecol Oncol 2007;105:132-7
61. Mangala LS, Zuzel V, Schmandt R, et al. Therapeutic targeting of ATP7B in ovarian carcinoma. Clin Cancer Res 2009;15:3770-80
62. Krieger ML, Eckstein N, Schneider V, et al. Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro. Int J Pharm 2010;389:10-17
63. Nguewa PA, Fuertes MA, Cepeda V, et al. Poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide enhances apoptosis induction by platinum complexes in cisplatin-resistant tumor cells. Med Chem 2006;2:47-53
64. Dabholkar M, Bostick-Bruton F, Weber C, et al. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 1992;84:1512-17
65. Sakai W, Swisher EM, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008;451:1116-20
66. Herzog TJ. Recurrent ovarian cancer: how important is it to treat to disease progression? Clin Cancer Res 2004;10:7439-49
67. Nishimura S, Tsuda H, Hashiguchi Y, et al. Phase II study of irinotecan plus doxorubicin for early recurrent or platinum-refractory ovarian cancer: interim analysis. Int J Gynecol Cancer 2007;17:159-63
68. Gupta D, Owers RL, Kim M, et al. A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers. Gynecol Oncol 2009;113:327-30
69. Polyzos A, Kosmas C, Toufexi H, et al. Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer. Anticancer Res 2005;25:3559-64
70. Kavanagh JJ, Gershenson DM, Choi H, et al. Multi-institutional phase 2 study of TLK286 (TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer. Int J Gynecol Cancer 2005;15:593-600
71. Wolf JK, Bodurka DC, Verschraegen C, et al. A phase II trial of oral capecitabine in patients with platinum-and taxane-refractory ovarian, fallopian tube, or peritoneal cancer. Gynecol Oncol 2006;102:468-74
72. Krasner CN, McMeekin DS, Chan S, et al. A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer 2007;97:1618-24
73. Caponigro F, Willemse P, Sorio R, et al. A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer. Invest New Drugs 2005;23:85-9
74. Vergote I, Finkler N, del Campo J, et al. Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or-resistant ovarian cancer. Eur J Cancer 2009;45:2324-32
75. Pisano C, Morabito A, Sorio R, et al. A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial. Cancer Chemother Pharmacol 2009;64:1021-7
76. Ramirez PT, Schmeler KM, Milam MR, et al. Efficacy of letrozole in the treatment of recurrent platinum-and taxane-resistant high-grade cancer of the ovary or peritoneum. Gynecol Oncol 2008;110:56-9
77. Seiden MV, Gordon AN, Bodurka DC, et al. A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer. Gynecol Oncol 2006;101:55-61
78. Coleman RL, Broaddus RR, Bodurka DC, et al. Phase II trial of imatinib mesylate in patients with recurrent platinum-and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol 2006;101:126-31
79. Seiden MV, Burris HA, Matulonis U, et al. A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol 2007;104:727-31
80. Nishio S, Sugiyama T, Shouji T, et al. Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum-and taxane-resistant epithelial ovarian cancer. Gynecol Oncol 2007;106:342-7
81. Gasent Blesa JM, Alberola Candel V, Provencio Pulla M, et al. Management of platinum-resistant ovarian cancer with the combination of pemetrexed and gemcitabine. Clin Transl Oncol 2009;11:35-40
82. Matsumoto K, Katsumata N, Yamanaka Y, et al. The safety and efficacy of the weekly dosing of irinotecan for platinum-and taxanes-resistant epithelial ovarian cancer. Gynecol Oncol 2006;100:412-16
83. Karaoglu A, Arslan UY, Ozkan M, et al. Efficacy and toxicity of gemcitabine and pegylated liposomal Doxorubicin in recurrent platinum-resistant/refractory epithelial ovarian cancer. Asian Pac J Cancer Prev 2009;10:63-6
84. Tas F, Guney N, Derin D, et al. A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer. Int J Clin Oncol 2008;13:156-60
85. Ojeda Gonzalez B, Gonzalez Martin A, Bover Barcelo I, et al. A phase II trial of fixed-dosed rate gemcitabine in platinum-resistant ovarian cancer: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) Trial. Am J Clin Oncol 2008;31:481-7
86. Matei D, Emerson RE, Schilder J, et al. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Cancer 2008;113:723-32
87. Abushahin F, Singh DK, Lurain JR, et al. Weekly topotecan for recurrent platinum resistant ovarian cancer. Gynecol Oncol 2008;108:53-7
88. Karagol H, Saip P, Uygun K, et al. The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer. Med Oncol 2007;24:39-43
89. Le T, Hopkins L, Baines KA, et al. Prospective evaluation of weekly topotecan in recurrent platinum-resistant epithelial ovarian cancer. Int J Gynecol Cancer 2008;18:428-31
90. Safra T, Ron I, Boaz M, et al. Heavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective outcome comparison between platinum-sensitive and platinum-resistant patients. Acta Oncol 2006;45:463-8
91. Matei D, Schilder J, Sutton G, et al. Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Gynecol Oncol 2009;115:90-6